chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Itchy rash; Very small pockets of liquid after the first dose (maybe 4) that only spread toscratched area after the second dose.; This is a spontaneous report from a contactable consumer, the patient. This is second of two reports. A 45-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EWO161) via an unspecified route of administration in the left arm on 20Apr2021 at 16:00 (at the age of 45-years-old) as a single dose for COVID-19 immunisation. Medical history included none. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. Concomitant medication was reported as none. The patient did not receive any medication within two weeks of vaccination. The patient previously took first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8732) via an unspecified route of administration in the right arm on 30Mar2021 at 16:00 (at the age of 45-years-old) as a single dose for COVID-19 immunisation and experienced very small pockets of liquid after the first dose maybe 4. The patient did not receive any other vaccines within four weeks prior to the vaccination. On an unknown date in 2021, the patient experienced very small pockets of liquid after the first dose maybe 4 that only spread to scratched area after the second dose. On 24Apr2021, the patient experienced Itchy rash within 2 days of getting the 2nd vaccine on both arms near the elbow joint similar to poison ivy. Patient stated that it eventually cleared up after a few weeks. Had not eaten anything new or been around any plants. The patient did not receive any treatment for the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events very small pockets of liquid, Itchy rash was recovering.   Follow-up attempts are completed. No further information is expected.
pt recvd vax;w/in 1.5 hrs of vax,pt devel approx 25 vesicles;5 vesicles at inject site,rest on upper torso;f/u info per RN,stated that vesicles due to flea bites;pt was playing w/ another child where dog was kept;oth child devel 15 vesicle
Vaccine was given to patient that was under 18 years of age.  Troubleshooting: This was missed in screening and the vaccinator did not ask for ID.
Approximately 15 minutes after vaccination, patient?s wife said he wasn?t feeling well. I found him sitting up right but not very respondent. Said he was blacking out, he couldn?t see well. He was barely audible and sweating. 911 was called at 11:17am.  Before EMS arrived he started to feel better and was conversing but waited for EMS. They arrived about 10 minutes later. He had a couple sips of water He was checked out. He said he hadn?t eaten all day and had never had a vaccine before. He walked out on his own with his wife
Swollen eye lids (top and bottom), rash on face, hands, necks. Itchy all over.   Throat tenderness and tight feeling
This case was reported by a other health professional and described the occurrence of expired vaccine used in a 3-month-old male patient who received ENGERIX B (batch number AHBVC103AA, expiry date 30th May 2014). On an unknown date, the patient received ENGERIX B. On an unknown date, an unknown time after receiving ENGERIX B, the patient experienced expired vaccine used. On an unknown date, the outcome of the expired vaccine used was unknown. Additional information received: HCP stated that 7 doses of expired ENGERIX-B were administered to patients. She said that her office does not pay attention to expiration dates very well. All patients received a dose from the same lot number and expiration date. This case is one of the 7 cases reported by the same reporter for the same vaccine.
Injection Fri 3:00 - ache/fatigue within 1st 24hrs. Fri pm & Sat. Ache/fatigue/headache/fever & nausea Sun & Mon stayed in bed - 2 full days. Ache/fatigue Tues - felt better Wed.
patient received first COVID dose from pharmacy on 2.15.2021 which was not documented in the patient chart and did not pull in from regulatory authority.  The regulatory authority has two accounts on this patient which may have contributed to the issue.  Patient received 4 doses of the vaccine as follows 2-15-2021 at pharmacy, 3-20-2021, 4-15-2021, and 9-30-2021.  request VAERS form be completed for documentation.
Sore arm; headache; low grade fever; tired; Achy; This is a spontaneous report from a contactable consumer. An 18-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8732) via an unspecified route of administration in the left arm on 24Mar2021 (at the age of 18-years-old) as a single dose for COVID-19 immunisation. Medical history was reported as unknown. Allergies to medications, food, or other products was reported as unknown. It was unknown if the patient had received any other medications within 2 weeks of vaccination. The patient previously received first dose of BNT162b2 (PFIZER BIONTECH COVID-19 mRNA VACCINE, lot number: unknown) on an unspecified date as a single dose for COVID-19 immunisation. The patient was not diagnosed with COVID-19 prior to the vaccination. The patient had not tested for COVID-19, since the vaccination. On 25Mar2021, the patient had experienced sore arm, headache, low grade fever, tired, and achy. The patient did not receive treatment for the reported events. Adverse events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events sore arm, headache, low grade fever, tired, and achy was resolved on an unknown date in Mar2021.   No follow-up attempts are needed. No further information is expected.  Amendment: This follow-up report is being submitted to amend previously reported information: added vaccine administration information.  No follow-up attempts are needed. No further information is expected.
Patient inadvertently received vaccine after published expiration date. Moderna company analyzed lot  007B21A and advised this lot maintained activity necessary to protect against covid 19 at time vaccine was administered. Patient also did not call in and complain of any adverse event. This is administrative error without adverse event.
This spontaneous report was received from a certified medical assistant concerning to an unspecified number of patients of unknown age and gender. Information regarding the patient's medical history, concurrent conditions or concomitant medication was not provided. Between 02-JUL-2015 and 04-AUG-2015, the patients were vaccinated with GARDASIL lot # K007828 with expiration date of: 02-MAR-2017, (strength, dose and route of administration were unknown). That was improperly stored at a temperature of 32F during 6 hours. No adverse events or product quality complaints were reported. Additional information has been requested.
Fever, body aches/joint pain, nausea, fatigue, headache .  Hot bath, ibuprofen, Tylenol, rest.  Missed 2 days of work.
I21.4 - Non-STEMI (non-ST elevated myocardial infarction) (CMS/HCC)
Facility lost power as a generator was being installed. Freezer temp fell out of range at this time which included Varicella vaccine. Freezer was not opened during the power outage.
Instantly felt tongue go numb. Within minutes, felt like tongue was starting to swell. Soon after lips felt numb and face.  Within ten minutes had a headache and stomach cramping.  By the time I got to the ER, tongue was very swollen.   They treated immediately with EpiPen, steroids, Benadryl and fluids. Tongue still swollen on day 2. I have a picture.
felt very weak; nausea; joint pain in my legs; severe dizziness; that I lost balance; vomiting; chills; strong headache; This is a spontaneous report from a contactable consumer (patient).   A 57-years-old non-pregnant female patient received the first dose of BNT162B2 (PFIZER-BIONTEC COVID-19 VACCINE, solution for injection; Lot Number: EP 7534) via an unspecified route of administration, administered in arm left on 20Mar2021 at 17:15 as dose 1, single (at the age of 57-years old) for covid-19 immunisation. The patient medical history was reported as none. Patient was not pregnant at the time of vaccination. The patient did not have allergies to medications, food, or other products were reported. The patient's concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The patient did not receive other medications within 2 weeks of vaccination. Prior to vaccination, patient was not diagnosed with COVID-19. On 28Mar2021 at 04:00, on Sunday, the patient experienced severe dizziness, that she lost balance, vomiting, chills and strong headache. Patient spent the day resting, hydrating and took (colecalciferol retinol) ADVIT (2 tablets). On 29Mar2021, on Monday, the patient felt very weak and experienced nausea, headache and joint pain in her legs. Patient took another dose of (colecalciferol retinol) ADVIT (2 tablets), she continued hydration. she felt better. It was possible to have side effect after 8 days of receiving the first dose. Since the vaccination, patient has not been tested for COVID-19. Therapeutic measures was taken as a result of all events ADVIT (2 tablets) and auto medication. The outcome of the events was recovering.   No follow-up attempts are needed. No further information is expected.
Narrative: COVID infection following COVID vaccine series 02/02, Pfizer, dose #1 02/18 COVID swab, result: not detected 02/23, Pfizer, dose #2 08/09 pt cc: cough, fatigue, headache, myalgias, sore throat exposure: unknown 08/11 COVID swab, result: detected 08/11 SARS-COV-2 LINEAGE result: B.1.617.2 08/11 SARS-COV-2 CLADE result: 21A
This spontaneous case was reported by an other health care professional and describes the occurrence of POOR QUALITY PRODUCT ADMINISTERED (Patient administered Moderna Covid vaccine while temperature excursion was ongoing) and PRODUCT TEMPERATURE EXCURSION ISSUE (Patient administered Moderna Covid vaccine while temperature excursion was ongoing) in a 38-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. No Medical History information was reported. On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On an unknown date, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Patient administered Moderna Covid vaccine while temperature excursion was ongoing) and PRODUCT TEMPERATURE EXCURSION ISSUE (Patient administered Moderna Covid vaccine while temperature excursion was ongoing). At the time of the report, POOR QUALITY PRODUCT ADMINISTERED (Patient administered Moderna Covid vaccine while temperature excursion was ongoing) and PRODUCT TEMPERATURE EXCURSION ISSUE (Patient administered Moderna Covid vaccine while temperature excursion was ongoing) outcome was unknown. For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments. It was reported that no adverse reactions were reported by patient. No concomitant medications were reported. No treatment information was reported.
2days p/vax mom stated leg was hot & swollen. size of baseball. seen in clinic dx w/lt lower extremely cellulitis. tx w/augmentin;
Treatment of COVID-19; Treatment of COVID-19; is pregnant: Pregnant; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 30-year-old female patient (pregnant) received BNT162b2 (BNT162B2), on 08Apr2022 as dose 4 (booster), single (Batch/Lot number: unknown) at the age of 30 years, in left arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Crohns disease" (unspecified if ongoing). Date of last menstrual period: 31Aug2021. The patient was 31 weeks pregnant at the time of exposure to BNT162b2. The patient was 31 weeks pregnant at the event onset. The patient is expected to deliver a baby(s) on 10Jun2022. Concomitant medication(s) included: LOVENOX [ENOXAPARIN SODIUM], start date: 01Dec2021; PRENATAL VITAMINS [MINERALS NOS;VITAMINS NOS], start date: 06Oct2021, stop date: 06Oct2021; REMICADE, start date: 01Nov2018. The following information was reported: MATERNAL EXPOSURE DURING PREGNANCY (non-serious) with onset 08Apr2022, outcome "unknown", described as "is pregnant: Pregnant"; DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "recovered with sequelae" and all described as "Treatment of COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Negative, notes: I tested negative on day 8; Negative, notes: tested negative on day 11; Positive, notes: positive with no symptoms on day 14. Therapeutic measures were taken as a result of drug ineffective, covid-19, maternal exposure during pregnancy. Patient received Paxlovid from start date: 03May2022 to 07May2022 for the treatment of COVID-19. Patient woke up with a sore throat on days 8, 9, and 10 of infection. she was also accompanied by a runny nose and headache. The symptoms were about 50% of the severity of the original infection. Patient was tested negative on day 8 and 11, positive with no symptoms on day 14.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 35-year-old male patient received BNT162b2 (BNT162B2), on 21May2022 at 12:00 as dose 4 (booster), single (Lot number: FK9893) at the age of 35 years, in right arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Crohn's Disease" (unspecified if ongoing). The patient's concomitant medications were not reported. Past drug history included: Amoxicillin, reaction(s): "Known allergies: Amoxicillin".  The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "not recovered" and all described as "Treatment of COVID-19". Therapeutic measures were taken as a result of drug ineffective, covid-19.  Clinical Course: Anti viral details: Product COVID 19 Treatment Paxlovid with lot number 1917015A, treatment start date was 13Jul2022, treatment stop date was 18Jul2022.
Information has been received from a registered nurse concerning a now 6 month old male child who on an unknown date was orally vaccinated with 2ml ROTATEQ (lot# unspecified). On an unknown date, the child experienced an increase in liver enzymes and ammonia levels. The child had sought medical attention by office visit. At the time of reporting, the child had not recovered. Additional information has been requested.
Patient has cross-inoculation on left arm and trunk area with minimal rash on trunk area.
I am an avid meditator and I have developed  tinnitus soon after my second shot I can not meditate , it is so laud and distracting . Hard to sleep due to the noise.
Sweats; Lethargy; Lack of appetite; Foggy headed; Insomnia; Chills; Body aches/severe body aches (similar to flu); Migraine like headache; Fever of 100.2F; Nausea; Swollen lymph nodes on right armpit; Sore injection site (injection site was right arm); This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 32 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm right, administration date 27Mar2021 (Lot number: ER8732) at the age of 32 years as dose 1, single and administered in arm right, administration date 17Apr2021 (Lot number: ER8735) as dose 2, single for covid-19 immunisation. Relevant medical history included: "Hypogammaglobulinemia" (unspecified if ongoing); "Asthma" (unspecified if ongoing); "restless leg" (unspecified if ongoing); "anxiety" (unspecified if ongoing); "Allergies: Sulfa" (unspecified if ongoing); "common variable immune deficiency" (unspecified if ongoing); "chronic fatigue syndrome" (unspecified if ongoing). Concomitant medication(s) included: LEXAPRO; ROPINIROLE; GAMUNEX C; TRIPHALA; VIT D; OM3GAFORT CHOLESTEROL. Past drug history included: Ceclor, reaction(s): "Known allergies: Ceclor". The following information was reported: HYPERHIDROSIS (non-serious) with onset 2021, outcome "not recovered", described as "Sweats"; LETHARGY (non-serious) with onset 2021, outcome "not recovered", described as "Lethargy"; DECREASED APPETITE (non-serious) with onset 2021, outcome "not recovered", described as "Lack of appetite"; FEELING ABNORMAL (non-serious) with onset 2021, outcome "not recovered", described as "Foggy headed"; INSOMNIA (non-serious) with onset 2021, outcome "not recovered", described as "Insomnia"; CHILLS (non-serious) with onset 2021, outcome "not recovered", described as "Chills"; PAIN (non-serious) with onset 2021, outcome "not recovered", described as "Body aches/severe body aches (similar to flu)"; HEADACHE (non-serious) with onset 2021, outcome "not recovered", described as "Migraine like headache"; PYREXIA (non-serious) with onset 2021, outcome "not recovered", described as "Fever of 100.2F"; NAUSEA (non-serious) with onset 2021, outcome "not recovered", described as "Nausea"; LYMPHADENOPATHY (non-serious) with onset 2021, outcome "not recovered", described as "Swollen lymph nodes on right armpit"; VACCINATION SITE PAIN (non-serious) with onset 2021, outcome "not recovered", described as "Sore injection site (injection site was right arm)". Relevant laboratory tests and procedures are available in the appropriate section.  Additional Information: The patient did not received any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19.  Follow-up attempts are completed. No further information is expected.
Postpartum month 6. Menorrhagia and purpuric rash over legs and oral mucosa about 1 week after vaccine administration. Thrombocytopenia on labs - 1000 platelet count. Given prednisone 100 mg by mouth daily. Platelet count rose to 37,000 in 10 days, but then started dropping again and in another 11 days was down to 8000. Given Anti-D Immune globulin- platelets rose to 87,000 2 days later and to 421,000 1 week after the Anti-D.  1/18/08 Reviewed hospital medical records which reveal patient experienced extremely heavy menstrual flow beginning on 11/6/07.  Next day she noted red spots on legs & oral mucosa, called her pcp who sent her to ER.  Exam revealed petechial rash & bruises.  Heme consult obtained.  Tx w/IV steroids w/improvement.  D/C to home on oral steroids w/heme f/u. FINAL DX: thrombocytopenia, possibly idiopathic thrombocytopenic purpura; hypocalcemia, resolved.
Fever, lethargy began 24 hrs after shots. The entire upper R arm swollen, red, hot, tender not localized abscess.
felt like dry lips; Dry mouth; Really thirsty; top lip was swollen; lips, tip of nose, and throat feel tingly now; felt tingly and dry underneath my lip; throat feel tingly; soreness on my arm; tightness on my chest with difficulty breathing; tightness on my chest with difficulty breathing; my mind was foggy.; it was hard for me to walk and I was incredibly tired; massive headache on my forehead; This is a spontaneous report from a contactable consumer, the patient. A 29-year-old female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EP7534), via an unspecified route of administration in the left arm on 20Mar2021 at 10:00 (at the age of 29-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma. The patient did not have any allergies to medications, food, or other products. It was unknown if the patient was pregnant at the time of vaccination. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive other medications within 2 weeks of vaccination. On 20Mar2021 at 10:00 approx. 20 seconds after the vaccine, the patient experienced massive headache on her forehead, shortly after that felt like a huge load was pushing her back into her seat. The patient wasn't able to keep conversations and her mind was foggy. It was hard for her to walk and she was incredibly tired. She slept most of the afternoon. At night before going to bed (at 21:00), she had a tightness on her chest with difficulty breathing and this was on Saturday. On 21Mar2021 (Sunday), all she had was soreness on her arm. On 23Mar2021 (Tuesday), she woke up around 4:10 with a dry mouth and what felt like dry lips. She was really thirsty and grabbed a cup of water and used the restroom. When she was washing my hands, she saw her face and noticed the top lip was swollen. It was so big that it overlapped her bottom lip. She felt tingly and dry underneath the lip. The patient continued to drink water and the swelling decreased not completely but it did go down. On 23Mar2021 at 09:07, the swelling decreased. The patient reported that the lips, tip of nose, and throat felt tingly now. The adverse events resulted in doctor or other healthcare professional office/clinic visit. It was unknown if the patient received any treatment for the events forehead headache, foggy feeling in head, tiredness, chest tightness, difficulty breathing, pain in arm, dry mouth, dry lips, thirst, swollen lips, tingling lips, tingling and tingling throat. The clinical outcome of the event swollen lips was recovering while that of forehead headache, foggy feeling in head, tiredness, chest tightness, difficulty breathing, pain in arm, dry mouth, dry lips, thirst, tingling lips, tingling and tingling throat was not recovered at the time of the report.   No follow-up attempts are needed. No further information is expected.
Shingles on right shoulder and right arm to elbow; evaluated by family doctor and diagnosis of shingles confirmed; patient treated with antiviral medication.
Patient received shot from pharmacist and it was higher in the arm, in the shoulder area. She had an adverse reaction, with rash, swelling and pain. She went to the MD and he prescribed physical therapy. She has been in physical therapy and still is in pain. She received the vaccine in September 2020.